Reading the tape
NASDAQ: CRNX
Crinetics Pharmaceuticals, Inc.
Healthcare · Biotechnology
Market Cap
$4.27B
52w High
$57.99
52w Low
$25.83
P/E
-8.24
Volume
931.33K
Outstanding Shares
104.71M
Price vs Fundamentals
Why The Stock Is Moving
Fundamentals are supporting the moveModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 21.1%Revenue (TTM): 421.66%FCF (TTM): -66.95%
What changed
The stock rose 21.1% over the last year. Revenue grew 421.66% over the trailing twelve months. Operating margin moved from -32,613.47% to -9,534.48%. Free cash flow declined 66.95% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum. The operating data is doing enough work that the move does not need an overvaluation story to explain it.
What would invalidate this read
Operating margin is at -9,534.48%. Revenue grew 421.66% — this thesis depends on that trajectory holding. Despite the price move, free cash flow fell 66.95%, which is worth watching as a leading indicator of future pressure. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Company profile
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors.
CEOR. Scott Struthers
SectorHealthcare
IndustryBiotechnology
Employees437
IPO dateJul 18, 2018
Valuation
Forward P/E—
EV/EBITDA-9.38
Enterprise value$4.33B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth—
Gross margin108.47%▼64.53%vs FY2024
Operating margin-9,534.48%▲79.41%vs FY2024
ROE-46.9%▼108.23%vs FY2024
Analyst consensus
RatingBuy
Target price$86.60▲112.52%
18
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$1.22 · Revenue est $8.51M
View